Quote · The Peter Attia Drive
#395 - Brain lipidology: understanding APOE, cholesterol homeostasis, Alzheimer's disease risk, and the effects of lipid-lowering therapies on brain health | Tom Dayspring, M.D.
Where this was said
Obicetrapib and CETP inhibition for cardiovascular and brain health
At 1:35:35 · chapter starts 1:31:00
Peter closes the pharmacology discussion with the most forward-looking topic: obicetrapib, a CETP inhibitor that inhibits the transfer of cholesterol from HDL to ApoB particles, causing HDL to enlarge and ApoA-1 to rise. The biological rationale for neuroprotection comes from genetics: people with natural CETP loss-of-function variants have lower rates of Alzheimer's disease and cognitive impairment. Pharmacologically mimicking this state could theoretically confer the same benefit [1] — Tom Dayspring "Obicetrapib, a CETP inhibitor, raises ApoA-1 and generates tiny protein-rich HDL particles that can cross the blood-brain barrier. The BROA…" 1:31:50 . Tom explains the cascade: obicetrapib enlarges HDL particles, the liver interprets the reduced free ApoA-1 as a deficiency and ramps up ApoA-1 production, and circulating ApoA-1 rises. These free ApoA-1 molecules and the tiny protein-rich HDL particles they form can cross the blood-brain barrier, fuse with brain ApoE HDL particles, and potentially convert dysfunctional APOE4 brain HDL into functional units capable of properly delivering cholesterol to neurons. The BROADWAY trial, conducted primarily for cardiovascular endpoints, measured Alzheimer's biomarkers — phosphorylated tau, amyloid-40/42 ratios, and fibrillary markers — and found movement in the right direction. New Amsterdam Pharma is now planning further trials with cognitive endpoints and possibly PET imaging. Tom and Peter are cautiously optimistic, noting that getting the timing and patient selection right — catching APOE4 carriers before irreversible pathology accumulates — will be the key challenge, citing the PREDIMED trial's early-halt success as a model for well-targeted primary prevention.
Researcher Bill Harris has concluded that an omega-3 index of 8–9% in red blood cell membranes reflects adequate omega-3 content across the body's cell membranes, though no randomized trial has proven a specific brain benefit.
Obicetrapib, a CETP inhibitor, raises ApoA-1 and generates tiny protein-rich HDL particles that can cross the blood-brain barrier. The BROADWAY trial showed movement in the right direction on phosphorylated tau, amyloid-40/42 ratios, and other Alzheimer's biomarkers — suggesting it may rescue dysfunctional APOE4 brain HDL.
People with genetic CETP loss-of-function variants have lower rates of Alzheimer's disease and cognitive impairment, providing the biological rationale for testing CETP inhibitors as a neuroprotective strategy.
